Soleno Therapeutics Inc
F:6XC1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Soleno Therapeutics Inc
F:6XC1
|
US |
|
Minaean SP Construction Corp
F:NJA
|
CA |
|
F
|
Fastenal Co
XBER:FAS
|
US |
|
R
|
Royal Unibrew A/S
LSE:0R6Z
|
DK |
|
S
|
Securitas AB
XMUN:S7MB
|
SE |
|
P
|
Principal Financial Group Inc
SWB:PG4
|
US |
|
S
|
Sumitomo Corp
XBER:SUMA
|
JP |
|
Lifeline SPAC I Oyj
F:0CD
|
FI |
|
E
|
eGain Corp
XBER:EGCA
|
US |
|
Oryzon Genomics SA
MAD:ORY
|
ES |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
US |
|
A
|
Ainmt ASA
F:AI6
|
NO |
|
I
|
Informa PLC
F:IEA
|
UK |
|
Oversea-Chinese Banking Corporation Ltd
F:OCBB
|
SG |
|
Quadient SA
F:NEQ0
|
FR |
|
A
|
Adcorp Holdings Ltd
JSE:ADR
|
ZA |
|
Oji Holdings Corp
OTC:OJIPF
|
JP |
Wall St Price Targets
6XC1 Price Targets Summary
Soleno Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 6XC1 is 0.17 EUR with a low forecast of 0.158 EUR and a high forecast of 0.248 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 6XC1's stock price target?
Price Target
0.17
EUR
According to Wall Street analysts, the average 1-year price target for 6XC1 is 0.17 EUR with a low forecast of 0.158 EUR and a high forecast of 0.248 EUR.
What is the Revenue forecast for Soleno Therapeutics Inc?
Projected CAGR
75%
Over the last 12 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 3 years is 75%.
What is the Operating Income forecast for Soleno Therapeutics Inc?
Projected CAGR
318%
The compound annual growth rate for Operating Income over the next 3 years is 318%.
What is the Net Income forecast for Soleno Therapeutics Inc?
Projected CAGR
187%
The compound annual growth rate for Net Income over the next 3 years is 187%.
